Indicators
Indicators
Value
Direction
MACD(12,26,9)
--
--
RSI(14)
--
--
STOCH(KDJ)(9,3,3)
--
--
ATR(14)
--
--
CCI(14)
--
--
Williams %R
--
--
TRIX(12,20)
--
--
StochRSI(14)
--
--
Mereo BioPharma Group PLC
MREO1.870USD
+0.030+1.63%
Close 11/28, 13:00（ET）Quotes delayed by 15 min
1.49BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Mereo BioPharma Group PLC
Currency: USD Updated: 2025-11-28Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Mereo BioPharma Group PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
9
analysts
Strong Buy
Current Rating
7.000
Target Price
+274.33%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Mereo BioPharma Group PLC Highlights
StrengthsRisks
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development. Etigilimab is an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity. Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late line ovarian cancer.
Overvalued
The company’s latest PE is -6.97, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 111.71M shares, decreasing 5.03% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 590.87K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.10.
Financial Health
Currency: USD Updated: 2025-11-28The company's current financial score is 7.58, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.45
Operational Efficiency
2.86
Growth Potential
10.00
Shareholder Returns
7.58
Mereo BioPharma Group PLC's Company Valuation
Currency: USD Updated: 2025-11-28The company’s current valuation score is 7.17, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -6.97, which is -32.55% below the recent high of -4.70 and -1216.88% above the recent low of -91.85.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 37/405
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-11-28The company’s current earnings forecast score is 9.11, which is higher than the Biotechnology & Medical Research industry's average of 8.02. The average price target for Mereo BioPharma Group PLC is 7.00, with a high of 9.00 and a low of 5.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
9
analysts
Strong Buy
Current Rating
7.000
Target Price
+274.33%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
523
Total
6
Median
6
Average
Company name
Ratings
Analysts
Mereo BioPharma Group PLC
MREO
9
CRISPR Therapeutics AG
CRSP
30
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
25
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
1
2
3
...
105
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-11-28The company’s current price momentum score is 8.93, which is higher than the Biotechnology & Medical Research industry's average of 7.23. Sideways: Currently, the stock price is trading between the resistance level at 1.98 and the support level at 1.70, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
--
--
MA10
--
--
MA20
--
--
MA50
--
--
MA100
--
--
MA200
--
--
Institutional Confidence
Currency: USD Updated: 2025-11-28The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.14. The latest institutional shareholding proportion is 70.22%, representing a quarter-over-quarter decrease of 10.37%. The largest institutional shareholder is James Simons, holding a total of 590.87K shares, representing 0.07% of shares outstanding, with 91.25% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2025-11-28The company’s current risk assessment score is 4.51, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.38. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.39
VaR
+7.20%
240-Day Maximum Drawdown
+60.10%
240-Day Volatility
+81.44%
Return
Best Daily Return
60 days
+9.60%
120 days
+9.60%
5 years
+62.50%
Worst Daily Return
60 days
-8.57%
120 days
-42.52%
5 years
-42.52%
Sharpe Ratio
60 days
+0.86
120 days
-0.50
5 years
+0.24
Risk Assessment
Maximum Drawdown
240 days
+60.10%
3 years
+68.79%
5 years
+92.55%
Return-to-Drawdown Ratio
240 days
-0.83
3 years
+0.50
5 years
-0.12
Skewness
240 days
-2.42
3 years
-0.40
5 years
+1.27
Volatility
Realised Volatility
240 days
+81.44%
5 years
+99.10%
Standardised True Range
240 days
+8.21%
5 years
+8.77%
Downside Risk-Adjusted Return
120 days
-44.85%
240 days
-44.85%
Maximum Daily Upside Volatility
60 days
+39.21%
Maximum Daily Downside Volatility
60 days
+31.34%
Liquidity
Average Turnover Rate
60 days
+0.30%
120 days
+0.24%
5 years
--
Turnover Deviation
20 days
-10.09%
60 days
+65.70%
120 days
+31.31%
Peer Comparison
Biotechnology & Medical Research
Mereo BioPharma Group PLC
MREO
7.73 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
NewAmsterdam Pharma Company NV
NAMS
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Zymeworks Inc
ZYME
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
MDGL
8.55 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Mereo BioPharma Group PLC?
The TradingKey Stock Score provides a comprehensive assessment of Mereo BioPharma Group PLC based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Mereo BioPharma Group PLC’s performance and outlook.
How do we generate the financial health score of Mereo BioPharma Group PLC?
To generate the financial health score of Mereo BioPharma Group PLC, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Mereo BioPharma Group PLC's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Mereo BioPharma Group PLC.
How do we generate the company valuation score of Mereo BioPharma Group PLC?
To generate the company valuation score of Mereo BioPharma Group PLC, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Mereo BioPharma Group PLC’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Mereo BioPharma Group PLC’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Mereo BioPharma Group PLC.
How do we generate the earnings forecast score of Mereo BioPharma Group PLC?
To calculate the earnings forecast score of Mereo BioPharma Group PLC, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Mereo BioPharma Group PLC’s future.
How do we generate the price momentum score of Mereo BioPharma Group PLC?
When generating the price momentum score for Mereo BioPharma Group PLC, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Mereo BioPharma Group PLC’s prices. A higher score indicates a more stable short-term price trend for Mereo BioPharma Group PLC.
How do we generate the institutional confidence score of Mereo BioPharma Group PLC?
To generate the institutional confidence score of Mereo BioPharma Group PLC, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Mereo BioPharma Group PLC’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Mereo BioPharma Group PLC.
How do we generate the risk management score of Mereo BioPharma Group PLC?
To assess the risk management score of Mereo BioPharma Group PLC, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Mereo BioPharma Group PLC’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Mereo BioPharma Group PLC.
